Kintor Pharmaceutical Limited
KNTPF
Other OTC0.23
USD
- -
- -
ISIN
KYG5273B1077
CUSIP
G5273B107
Return %
Stock
S&P500
1Y
29.90
19.01
3Y
-53.91
65.48
5Y
-97.05
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Youzhi Tong
- Full Time Employees
- 123
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 20 Songbei Road Suzhou JS People's Republic of China 215123
- IPO Date
- Dec 11, 2020
- Website
- kintor.com.cn
- Similar Companies
- Business
- Kintor Pharmaceutical Limited, a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Suzhou, China, develops innovative small-molecule drugs, biologics and combination therapies targeting unmet needs in dermatology and oncology, particularly androgen receptor-related diseases including androgenetic alopecia, acne vulgaris, prostate cancer and liver cancer. The company's core pipeline comprises KX-826, a topical AR antagonist in phase III trials for male AGA in China (with enrollment completed for 666 patients in July 2025) and phase II for acne and female AGA; AR-PROTAC compound GT20029, a topical PROTAC in phase II for acne (primary endpoint met in August 2025, 0.5% dosage recommended for phase III) and AGA; Hedgehog/SMO inhibitor GT1708F in phase II for idiopathic pulmonary fibrosis; mTOR kinase inhibitor GT0486; ALK-1 antibody GT90001 for solid tumors; and tyrosinase inhibitor KT-939 as a new cosmetic raw material for skin whitening with completed long-term safety trial enrollment in September 2025 and first global sales in May 2025. Kintor operates primarily in China, the US and other regions through clinical trials and commercialization efforts, including the launch of its high-end cosmetics brand KOSHINÉ in late 2024 featuring eight products such as anti-hair loss solutions, acne cream with KX-826 and whitening series with KT-939 sold via e-commerce platforms like Tmall, JD, Douyin and Amazon; recent advancements include positive top-line results from KX-826's phase II pivotal trial and long-term safety phase III for AGA in March-July 2025, GT20029 phase II for acne in August 2025, and KT-939's JNCI designation in Japan in June 2025 enabling market entry. Listed on the Hong Kong Stock Exchange (9939.HK; OTC: KNTPF) since May 2020, Kintor advances its pipelines via internal R&D platforms, in-house manufacturing in Suzhou Industrial Park and strategic global licensing pursuits.
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA